drugset / Trial / NCT01847664
Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the trial is to compare the efficacy of Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. placebo in patients with acute uncomplicated diverticulitis.
Timeline
- Start
- 2013-08
- Primary completion
- 2017-07
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifamycin SV MMX | Unknown | 400 mg | Oral |
| Subject | Rifamycin SV MMX | Unknown | 600 mg | Oral |